NeoSync is an early stage company
with a proprietary, platform technology that
it is using to develop advanced, non-invasive neuro-modulation products designed to treat neurological disorders. In 2011, NeoSync initiated a pivotal clinical trial in the U.S. for treating major depressive disorder (MDD), a disease that afflicts over 17 million Americans. For more detailed information about the clinical trial, please go to clinicaltrials.gov. The Company is led by experienced medical device executives and entrepreneurs. Headquartered in Waltham, MA, NeoSync is privately held.